PMID- 27886020
OWN - NLM
STAT- MEDLINE
DCOM- 20180412
LR  - 20180816
IS  - 1878-7401 (Electronic)
IS  - 0928-7329 (Linking)
VI  - 25
IP  - 3
DP  - 2017
TI  - Cranial electrotherapy stimulation affects mood state but not levels of 
      peripheral neurotrophic factors or hypothalamic- pituitary-adrenal axis 
      regulation.
PG  - 403-412
LID - 10.3233/THC-161275 [doi]
AB  - Cranial electrotherapy stimulation (CES) is reported to aid in relieving symptoms 
      of depression and anxiety, though the mechanism underlying this effect remains 
      unclear. Therefore, the present study aimed to evaluate changes in the 
      hypothalamic-pituitary-adrenal (HPA) axis response and levels of neurotrophic 
      factors, as well as changes in mood state, in patients undergoing CES therapy. 
      Fifty healthy postmenopausal women were randomly assigned to either a Sham CES 
      group (n = 25) or an Active CES group (n = 25). CES treatment was conducted in 
      20-minute sessions, three times per week for 8 weeks, using a micro current 
      cranial electrotherapy stimulator. Blood samples were collected prior to and 
      following the 8-week treatment period for measurement of cortisol, 
      adrenocorticotropic hormone (ACTH), brain-derived neurotrophic factor (BDNF), and 
      nerve growth factor (NGF) levels. Changes in mood state were also examined at the 
      time of blood collection using the Profile of Mood States (POMS). No significant 
      differences in cortisol, ACTH, BDNF, or NGF were observed between the two 
      participant groups (p > 0.05) following the treatment period. However, those in 
      the Active CES group exhibited significantly decreased Tension-Anxiety and 
      Depression-Dejection scores on the POMS relative to pre-treatment scores (p < 
      0.05). Furthermore, Depression-Dejection scores following treatment were 
      significantly lower in the Active CES group than in the Sham CES group (p < 
      0.05). No significant differences were observed in any other POMS scores such as 
      Anger-Hostility, Vigor-Activity, Fatigue-Inertia, and Confusion-Bewilderment (p > 
      0.05). These results suggest that 8 weeks of CES treatment does not induce 
      changes in blood levels of neurotrophic factors or HPA-axis-related hormones, 
      though such treatment may be effective in treating symptoms of anxiety and 
      depression.
FAU - Roh, Hee-Tae
AU  - Roh HT
AD  - Department of Physical Education, College of Arts and Physical Education, Dong-A 
      University, Busan, Korea.
FAU - So, Wi-Young
AU  - So WY
AD  - Sports and Health Care Major, College of Humanities and Arts, Korea National 
      University of Transportation, Chungju-si, Korea.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Technol Health Care
JT  - Technology and health care : official journal of the European Society for 
      Engineering and Medicine
JID - 9314590
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 7171WSG8A2 (BDNF protein, human)
RN  - 9002-60-2 (Adrenocorticotropic Hormone)
RN  - 9061-61-4 (Nerve Growth Factor)
RN  - WI4X0X7BPJ (Hydrocortisone)
SB  - IM
MH  - Adrenocorticotropic Hormone/blood
MH  - *Affect/physiology
MH  - Anxiety/therapy
MH  - Brain-Derived Neurotrophic Factor/*blood
MH  - Depression/therapy
MH  - *Electric Stimulation Therapy
MH  - Female
MH  - Humans
MH  - Hydrocortisone/blood
MH  - *Hypothalamo-Hypophyseal System/physiology
MH  - Middle Aged
MH  - Nerve Growth Factor/*blood
MH  - *Pituitary-Adrenal System/physiology
MH  - Psychiatric Status Rating Scales
OTO - NOTNLM
OT  - Cranial electrotherapy stimulation
OT  - anxiety
OT  - depression
OT  - mental health
OT  - neurotrophic factor
EDAT- 2016/11/26 06:00
MHDA- 2018/04/13 06:00
CRDT- 2016/11/26 06:00
PHST- 2016/11/26 06:00 [pubmed]
PHST- 2018/04/13 06:00 [medline]
PHST- 2016/11/26 06:00 [entrez]
AID - THC1275 [pii]
AID - 10.3233/THC-161275 [doi]
PST - ppublish
SO  - Technol Health Care. 2017;25(3):403-412. doi: 10.3233/THC-161275.